630116-52-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-METHYLPHENYL)PIPERIDINE is used as a precursor in the synthesis of various organic compounds for the development of new pharmaceuticals. Its unique structure allows for the creation of molecules with specific therapeutic properties, contributing to the advancement of drug discovery and medicinal chemistry.
Used in Psychoactive Drug Development:
As a psychoactive compound, 4-(2-METHYLPHENYL)PIPERIDINE is utilized in the research and development of drugs that can interact with the central nervous system. Its potential applications in this area may include the treatment of neurological disorders or the development of novel therapeutic agents for mental health conditions.
Used in Medicinal Chemistry Research:
4-(2-METHYLPHENYL)PIPERIDINE serves as a valuable compound in medicinal chemistry research, where it is studied for its potential to modulate biological targets and pathways. This can lead to the discovery of new drugs with improved efficacy and safety profiles, ultimately benefiting patients and the healthcare industry.
Used in Chemical Synthesis:
In the field of chemical synthesis, 4-(2-METHYLPHENYL)PIPERIDINE is used as a building block for creating a variety of complex organic molecules. Its versatility in forming different chemical structures makes it an essential component in the synthesis of specialty chemicals, materials, and other compounds with diverse applications.

Upstream product

• 694-05-3 1,2,3,6-tetrahydropyridine 
• 108-88-3 toluene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 95-46-5 2-methylphenyl bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 932-31-0 ortho-tolylmagnesium bromide 
• 16419-60-6 2-Methylphenylboronic acid 
• 651053-67-7 4-o-tolyl-4H-pyridine-1-carboxylic acid phenyl ester 
• 110-86-1 pyridine 
• 83674-75-3 1-benzyl-4-o-tolylpiperidin-4-ol 
• 6630-33-7 ortho-bromobenzaldehyde 
• 529-20-4 2-methylphenyl aldehyde 
• 24393-41-7 ethyl 2-cyano-3-(2-methylphenyl)acrylate 
• 34824-58-3 2-(2-bromophenyl)-1,3-dioxolan 

Downstream Products

• 82212-02-0 4-(2-methylphenyl)piperidine hydrogen chloride salt 
• 1189532-96-4 8-hydroxy-2-(4-o-tolylpiperidin-1-yl)naphthalene-1,4-dione 
• 1623467-77-5 3,3-diethyl-5-(4-o-tolyl-piperazin-1-ylmethyl)-dihydrofuran-2-one 

Relevant academic research and scientific papers

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

Bioisosteric replacement and related analogs in the design, synthesis and evaluation of ligands for muscarinic acetylcholine receptors

Previous structure-activity relationship studies involving a series of lactone-based muscarinic ligands identified a lead compound containing a diphenylmethylpiperazine moiety (4; IC50 = 340 nM). The purpose of the present work is to investigate 1,3-benzodioxoles, 4,4-diethyl substituted tetrahydrofurans, 5-substituted oxazolidinones and chromones as bioisosteric replacements for the lactone ring in a novel series of muscarinic ligands. The approach provided compounds with improved % inhibition values and identified a non-selective muscarinic ligand with an IC50 value of 280 nM. The structure-activity relationship for this new series will be discussed. Selected compounds were evaluated in preliminary assays for subtype selectivity and were found to be non-selective.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

LIGAND FOR VESICULAR ACETYLCHOLINE TRANSPORTER

The present invention provides a novel compound represented by the formula (I): wherein R1 and R2 are as defined in the specification, or a salt thereof, which is useful as a reagent (radiotracer) for VAChT mapping and the like, and can be used for positron emission tomography (PET), and a production method of the compound. Moreover, the present invention provides a diagnostic reagent for diagnosing cholinergic neurodegenerative disorders (e.g., Alzheimer's disease, memory disorder, learning disorder, schizophrenia, cognitive dysfunction, hyperactivity disorder, anxiety neurosis, depression, analgia, Parkinson's disease and the like) and the like, which contains the aforementioned compound.

CYCLOALKANOPYRIDINE DERIVATIVE

Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor

We synthesized methylvesamicol analogs 13-16 and investigated the binding characteristics of 2-[4-phenylpiperidino]cyclohexanol (vesamicol) and methylvesamicol analogs 13-16, with a methyl group introduced into the 4-phenylpiperidine moiety, to sigma receptors (σ-1, σ-2) and to vesicular acetylcholine transporters (VAChT) in membranes of the rat brain and liver. In competitive inhibition studies, (-)-o-methylvesamicol [(-)-OMV] (13) (Ki = 6.7 nM), as well as (-)-vesamicol (Ki = 4.4 nM), had a high affinity for VAChT. (+)-p-Methylvesamicol [(+)-PMV] (16) (Ki = 3.0 nM), as well as SA4503 (Ki = 4.4 nM), reported as a σ-1 mapping agent for positron emission tomography (PET), had a high affinity for the σ-1 receptor. The binding affinity of (+)-PMV (16) for the σ-1 receptor (Ki = 3.0 nM) was about 13 times higher than that for the sigma-2 (σ-2) receptor (Ki = 40.7 nM). (+)-PMV (16) (K i = 199 nM) had a much lower affinity for VAChT than SA4503 (K i = 50.2 nM) and haloperidol (Ki = 41.4 nM). These results showed that the binding characteristics of (-)-OMV (13) to VAChT were similar to those of (-)-vesamicol and that (+)-PMV (16) bound to the σ-1 receptor with high affinity. In conclusion, (-)-OMV (13) and (+)-PMV (16), which had a suitable structure, with a methyl group for labeling with 11C, may become not only a new VAChT ligand and a new type of σ receptor ligand, respectively, but may also become a new target compound of VAChT and the σ-1 receptor radioligand for PET, respectively.

Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2- yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist

High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas (3) as TRPV1 vanilloid receptor ligands. Exploration of the structure-activity relationships by parallel synthesis identified t

Efficient Solution-Phase Parallel Synthesis of 4-Substituted N-Protected Piperidines

Practical conditions for the synthesis of 4-substituted N-protected piperidines through CuCN·2LiBr-catalyzed organozinc additions to 1-acylpyridinium salts and subsequent hydrogen-transfer hydrogenation have been established. The reaction sequence is performed at room temperature and provides 4-substituted N-protected piperidines in excellent overall yields without the isolation of intermediate dihydropyridines, In those cases in which the organozinc addition results in mixtures of 2- and 4-substituted dihydropyridines, the 2-substituted isomers are efficiently scavenged with maleic anhydride and subsequently removed by a mild extractive workup with NaHCO3 (sat.). The N-acyl group can conveniently be exchanged from N-phenoxycarbonyl to N-tBoc, thus allowing orthogonal deprotection strategies. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.

Superacid-catalyzed preparation of aryl-substituted piperidines via dicationic electrophiles

The electrophilic chemistry of 1,2,3,6-tetrahydropyridines has been studied in the Bronsted superacid, CF3SO3H (triflic acid). The 1,2,3,6-tetrahydropyridines react with arenes to give aryl-substituted piperidines. It is proposed tha

Serine derived NK1 antagonists 2: A pharmacophore model for arylsulfonamide binding

Modifications to the spirocyclic aryl sulfonamide portion of serine derived NK1 antagonists allow a partial pharmacophore model to be developed.